BlackRock Seeks Staking Option for iShares Ethereum Trust in New Filing
The update signals that BlackRock is aiming to go beyond simple ether (ETH) exposure and participate in Ethereum's proof-of-stake consensus system. If approved, the ETF could stake a portion of its ETH holdings through one or more trusted providers to generate additional yield.
Ether staking involves locking up tokens to help secure the network in exchange for regular payouts. Several asset managers, including Franklin Templeton and Grayscale, have also proposed staking features in their Ethereum ETF filings. The SEC delayed its first deadline to make a decision on those proposals.
U.S. regulators have yet to definitively decide whether staking services offered through an ETF would qualify as securities activity. But the inclusion of staking in the BlackRock filing reflects growing confidence that staking could eventually be part of crypto ETFs.
The SEC is widely expected to greenlight a further wave of spot crypto ETFs this year after approving similar bitcoin and ether products last year.
ETHA is currently trading at $25.42 a share and has attracted over $7.2 billion in assets since its launch in June of last year.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
5 minutes ago
- Associated Press
Dubai Real Estate Market Embraces Cryptocurrency Transactions
DUBAI, UNITED ARAB EMIRATES, August 18, 2025 / / -- Investors in Dubai can now legally buy property using cryptocurrency, as the emirate continues its push to become a global leader in blockchain adoption and digital assets. This move opens new opportunities for international buyers seeking secure, transparent, and efficient property transactions. Industry platforms such as Crypto Homes DXB are at the forefront of this innovation, providing investors with access to residential and commercial properties purchasable via Bitcoin, Ethereum, USDT, and other leading cryptocurrencies. Why Cryptocurrency is Changing Real Estate Transactions Faster Transactions – Eliminates delays associated with traditional banking. Global Accessibility – Enables investors worldwide to purchase Dubai properties with ease. Enhanced Security – Blockchain ensures every transaction is transparent and verifiable. Future-Proof Investment – Aligns with Dubai's long-term vision of becoming a global digital economy hub. Frequently Asked Question Q: Can foreigners buy property in Dubai using cryptocurrency? Yes. Dubai permits international investors to purchase freehold properties using approved cryptocurrencies. Q: Which cryptocurrencies are accepted? Bitcoin, Ethereum, and USDT are currently among the most widely used. Q: Is it safe to buy property with crypto? Yes. Transactions are processed through blockchain, ensuring transparency and reducing risks. About Crypto Homes DXB Crypto Homes DXB is a Dubai-based platform bridging the gap between property and digital assets, offering buyers secure, blockchain-powered real estate transactions. Crypto Homes Crypto Homes DXB +971 50 903 9061 [email protected] Visit us on social media: LinkedIn Instagram Facebook YouTube TikTok X Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Associated Press
7 minutes ago
- Associated Press
ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Luminar Technologies, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action
New York, New York--(Newsfile Corp. - August 17, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Luminar Technologies, Inc. (NASDAQ: LAZR) between March 20, 2025 and May 14, 2025, both dates inclusive (the 'Class Period'), of the important September 22, 2025 lead plaintiff deadline. SO WHAT: If you purchased Luminar securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: To join the Luminar class action, go to or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 22, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) Austin Russell ('Russell'), Luminar's President, CEO and Chairman of the Board, was engaged in undisclosed conduct that would make him the subject of an inquiry by the Audit Committee of the Board of Directors; (2) this conduct created material risk that Russell would be released form his positions at Luminar; (3) Luminar's loss of Russell as an employee would then create material risk of adversely affecting Luminar's business by making it more difficult to compete with other market participants, manage R&D activities, and retain existing customers or cultivate new ones. Further, negative public perception and negative news related to Russell could adversely affect Luminar's brand relationships with customers, or standing in the industry; (4) accordingly, Luminar had no reasonable basis to provide and/or maintain Luminar's financial guidance; and (5) as a result, defendants' public statements were materially false and/or misleading at all times. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Luminar class action, go to or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. ------------------------------- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] To view the source version of this press release, please visit
Associated Press
8 minutes ago
- Associated Press
PureTech Health: Notice of Half-Yearly Results
BOSTON--(BUSINESS WIRE)--Aug 18, 2025-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ('PureTech' or the 'Company') plans to announce its half-yearly results for the six months ended June 30, 2025, on Thursday, August 28, 2025. A presentation and conference call for analysts and shareholders will take place at 9:00am EDT / 2:00pm BST on the day of publication, and a webcast of the presentation will be available on the Company's website at About PureTech Health PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep portfolio through its experienced research and development team and its extensive network of scientists, clinicians, and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including three that have been approved by the U.S. Food and Drug Administration. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration-enabling studies. All of the underlying programs and platforms that resulted in this portfolio of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points. For more information, visit or connect with us on X (formerly Twitter) @puretechh. Cautionary Note Regarding Forward-Looking Statements This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation those statements that relate to the timing of the Company's financial reporting and the Company's future prospects, developments, and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption 'Risk Factors' in our Annual Report on Form 20-F for the year ended December 31, 2024, filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise. View source version on CONTACT: PureTech Public Relations [email protected] Investor Relations [email protected] KEYWORD: MASSACHUSETTS UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: SCIENCE OTHER SCIENCE BIOTECHNOLOGY RESEARCH PHARMACEUTICAL HEALTH FDA CLINICAL TRIALS SOURCE: PureTech Health plc Copyright Business Wire 2025. PUB: 08/18/2025 02:00 AM/DISC: 08/18/2025 01:59 AM
